Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eyal C. Attar Insider Profile
4 Followers
Eyal C. Attar, SVP, Chief Medical Officer, Director at Aprea Therapeutics, holds 96.06K shares in Vor Biopharma (Ticker: VOR), holds 57.56K shares in Aprea Therapeutics (Ticker: APRE).
Eyal C. Attar has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Eyal C. Attar holds in companies
Most Profitable Insider Trade
The most profitable trade made by Eyal C. Attar
Eyal C. Attar's Trading History
Aprea Therapeutics
Jun 07, 2022
SVP, Chief Medical Officer, Director
Uninformative Sell
26.13K
$230.26K
Vor Biopharma
Jun 04, 2024
CMO
Uninformative Sell
20.36K
$88.67K
List of latest transactions for each holding click on a transaction to see Eyal C. Attar's performance on stock
You May Also Like
Eyal C. Attar insider profile FAQ
What is the percentage of profitable transactions made by Eyal C. Attar?
The percentage of profitable transactions made by Eyal C. Attar is ―.
What is the average return per transaction made by Eyal C. Attar?
The average return per transaction made by Eyal C. Attar is ―.
What stocks does Eyal C. Attar hold?
Eyal C. Attar holds: APRE, VOR stocks.
What was Eyal C. Attar’s latest transaction?
Eyal C. Attar latest transaction was an Uninformative Sell of $20.36K.
What was Eyal C. Attar's most profitable transaction?
Eyal C. Attar’s most profitable transaction was an Informative Buy of APRE stock on October 7, 2019. The return on the trade was 45.10%.
What is Eyal C. Attar's role in Aprea Therapeutics?
Eyal C. Attar's role in Aprea Therapeutics is SVP, Chief Medical Officer, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.